Background
Methods
Analytical methods
Patients and chemotherapy regimens
Resource utilization data and costs
Time horizon and discounts
Sensitivity analysis
Results
Characteristics of patients and chemotherapy regimens
Number of patients | 30 |
Sex | |
Male | 21 |
Female | 9 |
Age | |
−59 | 11 |
60–69 | 9 |
70− | 10 |
Average | 62.8 |
Site of colorectal cancer | |
Cecum | 4 |
Ascending colon | 3 |
Transverse colon | 2 |
Descending colon | 1 |
Sigmoid colon | 7 |
Rectum | 13 |
Rate of hospitalization | 23 % |
Overall treatment period (average) | 13.5 months |
Treatment lines | |
First-line | 30 |
Second-line | 20 |
Third-line | 8 |
Regimens | |
Oxaliplatin-based regimens | 13 |
FOLFOX | 12 |
XELOX | 1 |
Irinotecan-based regimens | 31 |
IRIS | 27 |
FOLFIRI | 4 |
Regimens including molecular targeted agents | 11 |
FOLFOX + Bev | 6 |
FOLFIRI + Bev or Cet | 4 |
XELOX + Bev | 1 |
Others | 3 |
First-line | Second-line | Third-line | Average durations of treatment (month) | |
---|---|---|---|---|
Total | 30 | 20 | 8 | 6.5 |
Oxaliplatin-based regimens | 2 | 11 | 3.9 | |
FOLFOX | 2 | 10 | 3.8 | |
XELOX | 1 | 5.0 | ||
Irinotecan-based regimens | 27 | 4 | 8.8 | |
IRIS | 27 | 9.3 | ||
FOLFIRI | 4 | 5.8 | ||
Regimens including molecular targeted agents | 1 | 8 | 2 | 4.3 |
FOLFOX + Bev | 6 | 5.0 | ||
FOLFIRI + Bev or Cet | 1 | 1 | 2 | 4.0 |
XELOX + Bev | 1 | 1.0 | ||
Others | 1 | 2 | 1.3 | |
Average durations of treatment (month) | 9.0 | 3.9 | 3.8 |
Costs
Total costs for the entire course of chemotherapy and costs according to regimen group
Total costs (mean) | 95 % CI | Minimum | 25th percentile | Median | 75th percentile | Maximum | |
---|---|---|---|---|---|---|---|
Overall treatment period (n = 30) | 308,363 | (258,792–357,933) | 152,345 | 208,653 | 270,328 | 340,179 | 637,299 |
First-line treatment (n = 30) | 256,149 | (207,992–304,307) | 149,816 | 186,293 | 208,555 | 261,922 | 637,299 |
Second-line treatment (n = 20) | 518,897 | (431,290–606,504) | 280,977 | 348,454 | 431,758 | 650,541 | 925,339 |
Third-line treatment (n = 8) | 416,251 | (188,316–644,185) | 141,582 | 162,033 | 297,117 | 600,389 | 1,056,666 |
Oxaliplatin-based regimens (n = 13) | 418,463 | (357,413–479,513) | 280,977 | 339,667 | 399,767 | 444,406 | 635,115 |
Irinotecan-based regimens (n = 31) | 215,499 | (188,359–242,639) | 141,867 | 171,990 | 207,516 | 223,415 | 567,549 |
Regimens including molecular targeted agents (n = 11) | 705,460 | (586,733–824,187) | 411,384 | 597,586 | 710,434 | 822,972 | 1,056,666 |
Cost-component analysis
Oxaliplatin-based regimens | Irinotecan-based regimens | Regimens including molecular targeted agents | |
---|---|---|---|
(n = 13) | (n = 31) | (n = 11) | |
mean (range) | mean (range) | mean (range) | |
Total | 418,463 (280,977–635,115) | 215,499 (141,867–567,549) | 705,460 (411,384–1,056,666) |
Outpatient visits | 6,051 (500–11,000) | 6,329 (3,540–11,000) | 5,375 (0–10,488) |
Hospitalization | 89,935 (14,022–209,077) | 53,584 (0–375,985) | 77,752 (0–192,950) |
Operations and Procedures | 37,353 (0–178,780) | 455 (0–9,860) | 38,222 (0–178,273) |
Tests | |||
Laboratory tests | 15,289 (4,991–38,970) | 11,757 (5,548–41,200) | 12,448 (5,833–24,173) |
Diagnostic imaging tests | 8,512 (0–29,140) | 24,039 (1,493–56,330) | 8,958 (0–23,118) |
Drugs and Administration | |||
Anticancer drugs | 228,539 (136,433–364,332) | 96,853 (58,335–138,086) | 535,214 (177,458–988,262) |
Antiemetics | 8,688 (6,051–19,636) | 9,232 (5,857–12,557) | 6,746 (365–11,972) |
Other drugs | 3,707 (0–19,128) | 708 (0–4,347) | 4,546 (0–32,316) |
Administration | 19,882 (2,200–44,160) | 12,543 (950–42,930) | 16,133 (950–43,610) |
Others | 508 (0–6,600) | 0 | 67(0–733) |
Proportion of hospitalization | 21 % | 25 % | 11 % |
Proportion of anticancer drugs | 58 % | 50 % | 77 % |
Meal fees | 8,677 | 4,001 | 4,639 |
Extra bed fees | 67,290 | 13,364 | 10,350 |
Sensitivity analysis
Oxaliplatin-based regimens | Irinotecan-based regimens | Regimens including molecular targeted agents | |
---|---|---|---|
(n = 13) | (n = 31) | (n = 11) | |
Base-case | 418,463 | 215,499 | 705,460 |
Hospitalization | 390,487 | 223,597 | 690,343 |
Outpatient | 327,177 | 160,287 | 627,033 |
Imaging Max | 433,991 | 215,499 | 720,541 |
Imaging Min | 418,463 | 199,972 | 705,013 |
Brand drug | 418,463 | 215,888 | 707,715 |
Generic drug | 404,097 | 214,046 | 694,883 |
Discussion
Oxaliplatin-based regimens | Irinotecan-based regimens | Regimens including molecular targeted agents | |
---|---|---|---|
Japan (Present study) | FOLFOX: 4,141 | IRIS: 2,217 | FOLFOX + Bev: 7,353 |
FOLFIRI (2nd line): 1,574 | FOLFIRI + Bev or Cet: 6,777 | ||
Japan (Miyazaki14) | FOLFOX: 4,151 | FOLFIRI: 2,398 | |
Japan (Shiroiwa15) | FOLFOX: 4,554 | FOLFIRI (2nd line): 2,376 | FOLFOX + Bev: 7,722 |
XELOX: 3,564 | IFL + Bev: 4,950 | ||
XELOX + Bev: 6,831 | |||
Japan (Ajima16) | FOLFOX: 5,352 | FOLFIRI: 3,743 | |
US (Mullins23) | FOLFOX: 60,179 (per patient) | FOLFIRI: 44,087 (per patient) | |
US (Tumeh24) | FOLFOX: 29,865 (per patient) | FOLFIRI: 24,551 (per patient) | |
US (Chu30) | FOLFOX: 14,300 | ||
XELOX: 11,473 | |||
UK (NICE:HTA200125) | FOLFOX: 5,718 | FOLFIRI: 5,975 | |
UK (NICE:HTA200826) | FOLFOX: 22,734 (per patient) | FOLFIRI: 23,017 (per patient) | |
UK (Tappenden27) | IFL: 40,998 (per patient) | IFL + Bev: 74,379 (per patient) | |
France (Perrocheau32) | FOLFOX: 23,597 (per patient) | ||
XELOX: 17,695 (per patient) | |||
Koria (Lee28) | FOLFIRI: 1,597 | Bev: 5,150 | |
UK (Ward31) | 5-FU/LV (Mayo): 2,065 | ||
Capecitabine: 1,225 | |||
UFT/LV: 1,944 |